Open-Label, Randomized, Dose Escalation Phase I Study in Healthy Adult Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody to Rabies (SII RMab) in Comparison to Human Rabies Immune Globulin Administered in Conjunction with Rabies Vaccine (RABIVAX).

Trial Profile

Open-Label, Randomized, Dose Escalation Phase I Study in Healthy Adult Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody to Rabies (SII RMab) in Comparison to Human Rabies Immune Globulin Administered in Conjunction with Rabies Vaccine (RABIVAX).

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Anti-rabies monoclonal antibody (Primary) ; Rabies immune globulin; Rabies vaccine
  • Indications Rabies
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2010 Results were presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 11 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India.
    • 09 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top